Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 8/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.76 |
| ▸ | HTT | P42858 | 5/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.76 |
| ▸ | HPGD | P15428 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 6/20 | 0.74 |
| ▸ | HRH1 | P35367 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615146 | 0.84 | MAPT (0.72) | HRH4TSHRMAPTHSD17B10HTT | |
| SCHEMBL615723 | 0.83 | HRH4 (1.00) | HRH4TSHRHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL3876311 | 0.82 | MAPT (0.73) | HRH4TSHRMAPTHSD17B10HTT | |
| SCHEMBL13771254 | 0.81 | MAPT (0.68) | HRH4TSHRMAPTHSD17B10HTT | |
| SCHEMBL3876308 | 0.81 | MAPT (0.70) | HRH4TSHRMAPTHSD17B10HTT | |
| SCHEMBL605038 | 0.79 | HRH4 (0.75) | HRH4TSHRMAPTHSD17B10HTT | |
| SCHEMBL16406269 | 0.75 | SMN1; SMN2 (0.67) | HRH4TSHRMAPTHSD17B10HTT | |
| SCHEMBL16905930 | 0.74 | HSD17B10 (0.59) | HRH4TSHRMAPTHSD17B10HTT | |
| SCHEMBL29554388 | 0.74 | MAPT (0.58) | HRH4TSHRMAPTHSD17B10HTT | |
| SCHEMBL18496060 | 0.74 | HRH4 (0.58) | HRH4TSHRMAPTHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022062357-A1 | MEDICINE FOR TREATING OR PREVENTING DISEASES RELATED TO ACTIVITY OF LRRK2 KINASE OR ABNORMAL LRRK2 MUTANT KINASE | 广州智睿医药科技有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2382013-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | ARGENTA DISCOVERY LTD. (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1812113-A1 | PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS | Argenta Discovery Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1776982-A1 | Pyrimidine compounds as histamine modulators | Argenta Discovery Limited (GB) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006050965-A1 | PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS | ARGENTA DISCOVERY LTD (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | HRH4, HRH3, HRH2 | HRH4 1/4885TSHR 1470/4885MAPT 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.